Resmed presents a once-in-10-year opportunity!

Marc Kennis Marc Kennis, October 6, 2023

Don’t be daft…buy ResMed

Stuart Roberts shares his views on ResMed (ASX:RMD) shares, which have seen a 30% decrease in value since the beginning of August. Stuart considers this sell-off to be an overreaction. He stresses the impact of weight loss drugs, such as Ozempic, doesn’t mean RMD’s business would start dwindling.

 

Don’t miss out on important news about ASX-listed stocks!

SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER!

 

Stuart highlights that ResMed has consistently maintained a high growth rate, even going back to before the global financial crisis. He anticipates that there will be a realisation that the underlying market for the company is substantially larger than the existing patient base. He rejects the interpretation that there is anything fundamentally wrong with the stock. Instead, he claims the company is in a stronger position now than ever before.

Stuart expects future growth will be driven by increased awareness of sleep apnea, investments in the company’s digital services and the existence of only three main competitors in the market.

Stuart commends ResMed’s successful investment of 7% of its revenue into R&D, yielding an array of impressive tools, setting the stage for sustained growth for the enterprise. Check out our recent article on Resmed!

 

Watch the interview below!

Stocks Down Under on Resmed (ASX:RMD)

 

Recent Posts

johns lyng group

Johns Lyng Group (ASX:JLG): One of a few ways to profit from climate change

Johns Lyng Group (ASX:JLG) is a restoration services company, repairing properties after damage by insured events, including weather and other…

hydrogen in australia

Hydrogen in Australia: Can we expect massive adoption in the next 10 years?

When will we see hydrogen in Australia? Not as a fad, not as an idea, but as a widespread energy…

Why is Gina Rinehart buying into Lynas

Why is Gina Rinehart buying into Lynas? She’s accumulated a stake worth over $300m

The big question on many investors’ minds this week is why is Gina Rinehart buying into Lynas? A substantial notice…